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bacteremia due to Moraxella catarrhalis in
children: a case–control study
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Abstract
Background: Invasive diseases due to Moraxella catarrhalis are rare in children, even in immunocompromised
hosts. Therefore, data regarding clinical characteristics and risk factors of such patients are limited. The aim of this
study is to compare the clinical characteristics of patients with bacteremia due to Moraxella catarrhalis against
those with bacteremia due to Streptococcus pneumoniae and Haemophilus influenzae.
Methods: We performed a retrospective case–control study to compare patients younger than 18 years of age
with positive blood cultures for the three pathogens between June 2008 and May 2014 at our institution. Data
regarding patients’ demographics and clinical course were collected from their medical records. Three group
comparisons, with M. catarrhalis as reference, were made by the Fisher’s exact test and Wilcoxon rank sum test
for discrete and continuous variables, respectively.
Results: There were eight cases of M. catarrhalis, 110 cases of S. pneumoniae (105 patients) and 22 cases of H.
influenzae. The M. catarrhalis group consisted of six females (75 %) with a mean age of 16 months. The majority of
patients (7/8, 88 %) had underlying diseases; however, only one was immunocompromised. Characteristically, six
patients (75 %) had medical devices including trans-nasal devices (5/8, 63 %). Univariate analysis revealed that
underlying conditions (P = 0.005), trans-nasal devices (P < 0.001), and lower body weight (P = 0.016) and low white
blood cell count (P = 0.011) at the onset of illness were associated with the M. catarrhalis group compared to the
S. pneumoniae group. Meanwhile, the higher rates of the patients with underlying conditions and trans-nasal
devices were associated with the M. catarrhalis group compared to the H. influenzae group (P = 0.039, P < 0.001,
respectively).
Conclusions: The presence of underlying conditions, particularly in those with trans-nasal devices, were
characteristic features of patients with bacteremia due to M. catarrhalis.
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Background
Streptococcus pneumoniae, Haemophilus influenzae and
Moraxella catarrhalis are recognized as the three most
common bacterial causes of respiratory infection in
children. In the pre-vaccine era, S. pneumoniae and H.
influenzae commonly caused invasive diseases including
bacteremia and meningitis. However, since the introduc-
tion of the pneumococcal conjugate vaccine (PCV) in
2000 and H. influenzae type b (Hib) vaccine in 1987 in
the United States, the number of patients with invasive
pneumococcal diseases (IPD) and invasive haemophilus
disease (IHD) has decreased remarkably [1–5]. Similarly,
in Japan, the incidence of patients with IPD or IHD has
decreased as a result of the introduction of PCV in 2010
and Hib vaccine in 2008 [6]. However, IPD caused by
non-vaccine serotype S. pneumoniae and respiratory dis-
eases by non-typable H. influenzae have since emerged
as a source of concern. Similarly, the relative importance
of M. catarrhalis as a cause of respiratory tract infection
such as otitis media, sinusitis and lower respiratory tract
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disease in otherwise healthy children and elderly persons
has been recognized [7]. Invasive diseases due to M. cat-
arrhalis are rare in children even in immunocomprom-
ised hosts [7, 8]. Hence, data regarding the clinical
characteristics and risk factors of patients with invasive
M. catarrhalis infection are limited. Identification of
patients at risk for invasive infection caused by M. catar-
rhalis, is important when considering empiric therapy
because most of the strains are beta-lactamase (penicil-
linase) producers, in contrast to pneumococcus. The
aim of this study is to investigate the characteristics of
the patients with bacteremia caused by M. catarrhalis
compared to those with bacteremia caused by S. pneu-
moniae or H. influenzae.
Methods
Setting and patients selection
We retrospectively identified patients with positive blood
cultures for M. catarrhalis, S. pneumoniae or H. influen-
zae at the National Center for Child Health and Devel-
opment (NCCHD). The NCCHD is a 490-bed tertiary
care children’s hospital in Tokyo, Japan, with approxi-
mately 12,000 hospitalizations and 35,000 visits to the
emergency department each year. The study period was
between June 2008 and May 2014. Patients with a dis-
ease onset at ≥18 years of age were excluded.
Data collection
Blood culture results were extracted from the infectious
disease surveillance system (Nippon Becton Dickinson
Company, Ltd, Tokyo, Japan) at NCCHD. Clinical data
of patients who were included were retrospectively col-
lected using electronic medical records, which were
reviewed for: 1) patients’ demographics including age,
gender, body weight, underlying medical conditions and
diseases, immunization records for PCV and Hib vac-
cine, medical devices, presence or absence of immuno-
deficiency, immunosuppressants, and previous antibiotic
use; 2) contact with sick person or people, symptoms, la-
boratory results at presentation, and focus of infection;
and 3) management including treatment and disposition,
as well as outcome.
Definitions
The focus of infection was defined based on the clinical
diagnosis or simultaneous identification of the pathogen
from the suspected focus (e.g. thoracic empyema, arth-
ritis, and meningitis) and the blood. Occult bacteremia
was defined based on the criteria from a previous report.
[9] Immunodeficiency was defined as follows: 1) primary
immunodeficiency including asplenia; 2) immunosup-
pressant use such as calcineurin inhibitors, steroids (a dos-
age equivalent to ≥2 mg/kg/day of prednisone or ≥20 mg/
day for children who weigh more than 10 kg, for more
than 14 days) [10]; and molecular-targeted agents (e.g. ri-
tuximab, infliximab); and 3) undergoing or <6 months
after completion of cancer chemotherapy. Medical devices
included any of the following; 1) central venous catheter
(peripherally inserted central catheter, short-term (non-
tunneled) central venous catheter, long-term (tunneled)
central venous catheter), 2) urinary catheter, 3) intubation
(nasotracheal or orotracheal) and tracheostomy, 4) naso-
gastric tube and elemental diet tube, 5) esophageal therm-
ometer, and 6) other foreign bodies. Onset of disease was
defined as community or nosocomial based on 1) whether
the patient was hospitalized within 1 month from the on-
set of illness, and 2) the site at which blood culture sam-
pling occurred (in an outpatient clinic or during
hospitalization). Hospital-acquired infection was defined
as infection with an onset of illness of more than three
days after admission to our hospital. Prior antibiotics use
was defined as patients who received antibiotics (oral or
intravenous agents) within one week prior to the onset of
illness. Duration of fever was defined as the number of
days the patient was on antibiotics until defervescence
was achieved for more than 24 h without antipyretics. Re-
currence was defined as bacteremia or invasive infection
due to the same organism within one month of comple-
tion of therapy.
Microbiological methods
Identification of each organism and antimicrobial sus-
ceptibility test were performed at our institution. Blood
cultures were inoculated into BacT/ALERT® 3D bottles
(SYSMEX bioMérieux Co., Ltd., Tokyo, Japan). M. catar-
rhalis, S. pneumoniae and H. influenzae were identified
using standard methods (BD Phoenix™ Automated
Microbiology System, Becton, Dickinson and Company,
NJ, USA). Antimicrobial susceptibility was determined
according to the criteria of the Clinical and Laboratory
Standards Institute [11].
Japanese immunization program
The PCV7 and Hib vaccines became available in Japan
in December 2008 on a voluntary basis and became fed-
erally funded for children since November 2010. Both
vaccines became part of the national immunization pro-
gram in April 2013. PCV7 was converted to PCV13 in
November 2013 [12, 13]. Current immunization sched-
ule recommended by the Japan Pediatric Society is avail-
able on the website [14].
Statistical analysis
Patients’ background and disposition data were summa-
rized by mean, standard deviation (SD), interquartile
range and proportion as appropriate. The comparisons
of M. catarrhalis vs. S. pneumoniae and M. catarrhalis
vs. H. influenzae were made by the Fisher’s exact test
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and Wilcoxon rank sum test for discrete and continuous
variables, respectively. We considered a p-value of less
than 0.05 as a meaningful difference. No adjustment for
multiplicity was conducted. The R software (version
3.1.2) [15] was used for statistical calculation.
Ethics
This study was performed under the institutions opt-out
passive consent policy and approved by the ethics
committee and the Institutional Board of Privacy and
Security at the National Center for Child Health and De-
velopment. Patients and guardians wishing to withdraw
from the study were able to contact the principal investi-
gator through information provided on notifications
publically posted by the institution’s ethics committee.
Patients were withdrawn based on verbal request from
the patient or the guardian (if patients were under
18 years of age at the time of request). Individual partici-
pant data is not reported.
Results
Patients/Cases
Patients included during the study period were as
follows: 1) M. catarrhalis (n = 8), 2) S. pneumoniae (n =
105 [110 cases]) and 3) H. influenzae (n = 22). (Figure 1)
Pneumococcal bacteremia gradually decreased after fed-
eral funding became available for PCV7 and PCV13.
Bacteremia due to Hib decreased remarkably after intro-
duction of Hib vaccine with no patients observed after
April 2012. One patient developed bacteremia due to
non-typable H. influenzae in May 2014, while bacteremia
due to M.catarrhalis occurred sporadically.
Baseline characteristics
Baseline characteristics among each group are shown
in Table 1.
M. catarrhalis
There were eight cases with bacteremia due to M. catar-
rhalis. Mean age was 16 months and six (75 %) were fe-
male. Majority of the patients (7/8, 88 %) had underlying
diseases. All but one patient were immunocompetent.
Characteristically, six patients (75 %) had medical device,
including trans-nasal devices (5/8, 63 %). Trans-nasal
devices included nasogastric tube (n = 3), elemental diet
tube (n = 2) and nasotracheal tube (n = 1). None of the
patients was on antibiotics prior to the onset of illness.
Six patients (75 %) developed hospital acquired infection
and two (25 %) were admitted to the pediatric intensive
care unit (PICU). Clinical characteristics of the patients
with bacteremia caused by M. catarrhalis are shown in
detail in Table 2. The focus of infection included
pneumonia (n = 4) and bronchitis (n = 3). Two out of
eight patients had concomitant infection with other
Fig. 1 Quarterly number of patients with bacteremia caused by Moraxella catarrhalis, Streptococcus pneumoniae, or Haemophilus influenzae. X-axis
denotes quarterly periods between April 2008 and June 2014. Y-axis denotes the incidence of bacteremia caused by M. catarrhalis, S. pneumoniae
and H. influenzae. Abbreviations: Hib, Haemophilus influenzae type b; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal
conjugate vaccine; NIP, national immunization program in Japan
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Table 1 Patients’ characteristics with bacteremia due to Moraxella catarrhalis, Streptococcus pneumoniae and Haemophilus influenzae
M. catarrhalis S. pneumoniae H. influenzae p-value* p-value**
(n = 8) (n = 110) (n = 22)
Age (months, mean ± SD) 16 ± 12 35 ± 32 25 ± 33 - -
Gender (female, %) 6 (75 %) 51 (46 %) 6 (27 %) 0.153 0.188
Body weight (kg)
mean ± SD 8.31 ± 2.80 12.49 ± 6.15 10.20 ± 3.10 0.016a 0.188
IQR 7.45-9.25 8.70-13.60 8.30-10.88
Vaccination
PCV7
YES (n, %) 6 (75 %) 25 (23 %) 1 (5 %) 0.004a <0.001a
PCV13
YES (n, %) 0 (0 %) 1 (1 %) 0 (0 %) N/A N/A
Hib vaccine
YES (n, %) 5 (63 %) 32 (29 %) 2 (9 %) 0.106 0.007a
Underlying diseases
YES (n, %) 7 (88 %) 39 (35 %) 9 (41 %) 0.005a 0.039a
Immunodeficiency
YES (n, %) 1 (13 %) 14 (13 %) 1 (5 %) 1.000 0.469
Immunosuppressants
YES (n, %) 2 (25 %) 7 (6 %) 0 (0 %) 0.114 0.064
Devices
YES (n, %) 6 (75 %) 18 (16 %) 0 (0 %) 0.001a <0.001a
Trans-nasal devices
YES (n, %) 5 (63 %) 7 (6 %) 0 (0 %) <0.001a <0.001a
History of previous intubation
YES (n, %) 5 (63 %) 32 (29 %) 4 (18 %) 0.106 0.032a
Contact with sick people
YES (n, %) 2 (25 %) 45 (41 %) 10 (45 %) 0.472 0.419
Pre-existing antibiotics
YES (n, %) 0 (0 %) 38 (38 %) 10 (45 %) 0.049a 0.029a
Hospital acquired infection
YES (n, %) 6 (75 %) 18 (16 %) 1 (5 %) 0.001a <0.001a
Symptoms
Rhinorrhea (n, %) 2 (25 %) 53 (48 %) 3 (14 %) 0.281 0.589
Cough (n, %) 5 (63 %) 44 (40 %) 5 (23 %) 0.274 0.078
Convulsion (n, %) 1 (13 %) 31 (28 %) 8 (36 %) 0.445 0.374
Vomiting (n, %) 2 (25 %) 14 (13 %) 1 (5 %) 0.296 0.166
Diarrhea (n, %) 1 (13 %) 6 (5 %) 2 (9 %) 0.350 1.000
Body temperature
Tmax (°C, mean) 38.9 39.3 39.0 0.176 0.557
IQR 38.6–39.2 38.7–40.0 38.5–39.8
Focus of infection
Occult bacteremia 0 (0 %) 40 (36 %) 2 (10 %) 0.050 1.000
Pneumonia 4 (50 %) 19 (17 %) 5 (22 %) 0.046 0.195
Meningitis 0 (0 %) 4 (4 %) 8 (36 %) 1.000 0.071
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pathogens; rotavirus gastroenteritis (n = 1) and respira-
tory syncytial virus infection (n = 1). All isolated strains
of M. catarrhalis were beta-lactamase producers. All but
one patient were empirically treated with appropriate
antibiotics for M. catarrhalis (cefotaxime [n = 2], ampi-
cillin/sulbactam [n = 2], ceftriaxone [n = 1], piperacillin/
tazobactam [n = 1], cefotiam [n = 1], and vancomycin [n
= 1]). The patient empirically treated with vancomycin
(for just one day) was switched to cefotaxime soon after
the identification of positive blood culture. Three pa-
tients were switched to oral antibiotics. The median dur-
ation of treatment was 14 days (range: 13–14). All
patients recovered without any recurrence or death after
the completion of antimicrobial therapy.
S. pneumoniae
There were 110 cases (105 patients) with bacteremia due
to S. pneumoniae. Mean age was 35 months and 51
(46 %) were female. Of all patients included, only 26 pa-
tients (24.8 %) had received PCV 7 and /or PCV13.
Thirty-nine (35 %) patients had underlying disease or
condition such as malignancy (n = 7), post liver trans-
plantation (n = 3), congenital heart diseases (n = 3),
asplenia (n = 2) and cerebrospinal fluid leak (n = 1).
There were 52 penicillin susceptible S. pneumoniae iso-
lates, 22 penicillin intermediate isolates and 36 penicillin
resistant isolates. The focus of infection was pneumonia
(n = 19), otitis media (n = 7), sinusitis (n = 6) and menin-
gitis (n = 4), but the majority had no apparent focus and
Table 1 Patients’ characteristics with bacteremia due to Moraxella catarrhalis, Streptococcus pneumoniae and Haemophilus influenzae
(Continued)
Otitis media/Sinusitis 0 (0 %) 13 (12 %) 1 (5 %) 0.596 1.000
Others 3b(38 %) 10c(9 %) 5d(22 %) 0.048 0.643
Unknown 1 (12 %) 24 (22 %) 1 (5 %) 1.000 0.469
Empiric antibiotic therapye
Aminopenicillinsf 0 (0 %) 19 (17 %) 0 (0 %) 0.351 N/A
Beta-lactam/Beta-lactamase inhibitor combinationsg 3 (38 %) 8 (7 %) 1 (5 %) 0.026 0.048
Second generation cephalosporinsh 1 (12 %) 2 (2 %) 0 (0 %) 0.191 0.267
Third generation cephalosporinsi 3 (38 %) 71 (65 %) 17 (77 %) 0.147 0.078
Othersj 1 (12 %) 17 (15 %) 8 (36 %) 1.000 0.374
No treatment 0 (0 %) 3 (3 %) 2 (9 %) 1.000 1.000
Initiation with combination therapy 0 (0 %) 10 (9 %) 6 (27 %) 1.000 0.155
Duration of fever after treatment (days, mean ± SD) 2.63 ± 0.92 1.86 ± 1.00 3.77 ± 3.61 0.012a 0.599
IQR 2–3 1–2 2–4.75
WBC (/μL, mean ± SD) 14,774 ± 13,750 19,706 ± 7862 17,805 ± 10,173
IQR 9395–12,158 14,548–24,318 9468–22,988 0.011a 0.277
ANC (/μL, mean ± SD) 11,395 ± 13,884 14,690 ± 7569 12,057 ± 7662
IQR 5220–9049 8984–19,408 6964–15,575 0.025a 0.237
CRP (mg/dL, mean ± SD) 1.86 ± 1.47 5.65 ± 6.68 8.09 ± 8.60
IQR 1.00–2.68 1.00–8.03 1.30–15.08 0.114 0.091
Hospitalization
YES (n, %) 7 (88 %) 84 (76 %) 14 (64 %) 0.680 0.374
ICU admission
YES (n, %) 2 (25 %) 9 (8 %) 1 (5 %) 0.162 0.166
*p-value for S. pneumoniae, compared to M. catarrhalis, **p-value for H. influenzae, compared to M. catarrhalis
aindicates significant (p < 0.05)
binclude bronchitis (n = 3)
cinclude pyothorax (n = 2), spontaneous bacterial nephritis (n = 2), periorbital cellulitis (n = 2), arthritis (n = 1), mastoiditis (n = 1), infective endocarditis (n = 1), and
infectious pericarditis (n = 1)
dinclude periarthritis (n = 1), urosepsis (n = 1), buccal cellulitis (n = 1), osteomyelitis (n = 1), and periorbital cellulitis (n = 1)
eAntimicrobial combination therapy was empirically initiated in a part of patients. (10 in S.pneumoniae group and 6 in H.influenzae, group)
finclude ampicillin and amoxicillin
ginclude ampicillin/sulbactam, amoxicillin/clavulanate, piperacillin/tazobactam, and cefoperazone/sulbactam
hinclude cefotiam and cefaclor
iinclude cefotaxime, ceftriaxone, and cefditoren pivoxil
jinclude piperacillin, cefazolin, cefepime, clindamycin, vancomycin, meropenem, panipenem/betamipron, amikacin
Abbreviations: interquartile range, IQR; 7-valent pneumococcal conjugate vaccine, PCV7; 13-valent pneumococcal conjugate vaccine, PCV13; Haemophilus
influenzae type b, Hib; white blood cell count, WBC; absolute neutrophil count, ANC; C-reactive protein, CRP; intensive care unit, ICU; not available, N/A
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1 female 5 8.3 Biliary atresia - YES (ED tube) NO Rhinorrhea Cough None Bronchitis Hospital NO -
2 female 7 3.1 ELBWI, CLD Multiple malformation - NO YES Cough None Pneumonia Hospital YES Pneumothorax
3 female 8 9.0 Bilateral hydronephrosis - NO YES Vomiting, Diarrhea None Unknown Community NO Rotavirus (+)a
4 male 9 7.7 none - YES (ETT, NG
tube)
NO Cough None Bronchitis Community NO RSV (+)b




NO - None Pneumonia Hospital YES -
6 female 18 6.7 VACTER association, ELBWI, CLD,
cAVB, DORV/PS/MS
- YES (ED tube,
PM)
NO Rhinorrhea Cough None Pneumonia Hospital NO
7 male 20 8.8 SDH, vascular ring - YES (NG tube) NO Vomiting, Wheeze
Convulsion
None Bronchitis Hospital NO -
8 female 44 12.9 Congenital intestinal motor
dysfuntion
- YES (CVC) NO Cough None Pneumonia Hospital NO -
aindicates concomitant infection with rotavirus diagnosed by rapid antigen test
bindicates concomitant infection with respiratory syncytial virus by rapid antigen test
Abbreviations: BW body weight, ELBWI extremely low birth weight infant, CLD chronic lung disease, VACTER Vertebral-Anal-Cardiac-Tracheoesophageal fistula-Renal, cAVB complete atrioventricular block, DORV double
outlet right ventricle, PS pulmonary stenosis, MS mitral stenosis, SDH subdural hemorrhage, TAC tacrolimus, mPSL methyl prednisolone, ED elemental diet, ETT endotracheal tube, NG nasogastolic, PM pacemaker, CVC












was classified as occult bacteremia (n = 40). Of the 84
hospitalized patients (76 %), nine (8 %) were admitted to
PICU. Twenty-one patients (24 %) were treated at the
outpatient clinic. Empiric antimicrobial therapy is de-
tailed in Additional file 1: Table S1. Of all patients with
S. pneumoniae, two patients had recurrences; one was
previously immunocompetent with congenital cyto-
megalovirus infection who developed four episodes of
bacteremia, and the other was immunocompromised
with medulloblastoma who received surgical, chemo-
radiotherapy and peripheral blood stem cell transplant-
ation and had a recurrence of bacteremia two weeks
after a treatment with piperacillin (100 mg/kg/day) for 6
days.
H. influenzae
There were 22 cases with bacteremia due to H. influen-
zae. All but one was caused by H. influenzae type b.
Mean age was 25 months and 16 (73 %) were male. Of
all the patients included with bacteremia due to H. influ-
enzae, only one (5 %) had received the Hib vaccine. Nine
(41 %) patients had underlying disease or condition such
as trisomy 21 (n = 2), asplenia (n = 1), Cornelia-de-Lange
syndrome (n = 1), Prader-Willi syndrome (n = 1), asthma
(n = 1), leukemoid reaction with unknown cause (n = 1),
anterior urethral valve with vesicoureteral reflux (Grade
III) and neurogenic bladder (n = 1), as well as swallowing
dysfunction and rhinopharynx reflux with upper airway
stricture (n = 1). No patient received immunosuppres-
sants or had medical device. Bacteremia was due to non-
typeable H. influenzae in one case and the rest were due
to Hib. Common sites of infection were the central ner-
vous system (meningitis [n = 8]) and lungs (pneumonia
[n = 5]). Of the 14 (64 %) patients hospitalized, one pa-
tient with meningitis was admitted to PICU. Empiric
antimicirobial therapy is detailed in Additional file 1:
Table S1. The rate of initiating combination antibiotic
therapy was highest (27 %) among three groups.
Comparison of patients’ characteristics
1) M. catarrhalis versus S. pneumoniae
The results of univariate analysis comparing the
characteristics of patients with bacteremia due to M.
catarrhalis (Moraxella group) and those with
bacteremia due to S. pneumoniae (Pneumococcus
group) are shown in Table 1. Moraxella group had
lower body weight, higher rate of patients with
underlying diseases or conditions and medical
devices, particularly trans-nasal devices, compared
to the pneumococcus group (P = 0.016, P = 0.005,
P = 0.001, and P < 0.001, respectively). In addition, a
higher rate of disease onset during hospitalization
and lower white blood cell count were noted in the
Moraxella group compared with the pneumococcus
group (P < 0.001, P = 0.011, respectively). A higher
rate of patients was on antibiotics in the pneumo-
coccus group (P = 0.049). The percentage of patients
with a history of contact with sick people and symp-
toms at the time of onset of illness were not differ-
ent between the two groups (P = 0.472, P = 0.281
[for rhinorrhea], P = 0.274 [for cough], P = 0.445
[for convulsion], P = 0.296 [for vomiting], P = 0.350
[for diarrhea], respectively). Presence or absence of
immunodeficiency and immunosuppressant use was
not significantly different between the two groups.
Duration of fever after appropriate treatment was
approximately one day longer in the Moraxella
group than in the pneumococcus group (P = 0.012).
2) M. catarrhalis versus H. influenzae
The results of univariate analyses regarding the
relationship between the patients with bacteremia
due to M. catarrhalis (Moraxella group) and those
with bacteremia due to H. influenzae (Haemophilus
group) are shown in Table 1. The Moraxella group
had a higher rate of patients with disease or
condition and medical devices, especially trans-nasal
devices, compared with the Haemophilus group
(P = 0.039, P < 0.001, and P < 0.001, respectively). In
addition, a lower percentage of the patients were on
antibiotics prior to presentation and a higher per-
centage of those with history of intubation were
noted in the Moraxella group compared with the
Haemophilus group (P = 0.029, P = 0.032,
respectively).
Discussion
Our study demonstrated that patients with bacteremia
due to M. catarrhalis were more likely to have under-
lying diseases or conditions, which necessitated the use
of medical devices, such as trans-nasal devices, in com-
parison with those with bacteremia due to S. pneumo-
niae or H. influenzae. To the best of our knowledge, this
is the first report that describes the differences in back-
ground and clinical characteristics of M. catarralis
bacteremia compared with pneumococcal and H. influ-
enzae bacteremia.
M. catarrhalis is regarded as one of the most common
bacterial causes of respiratory tract infections, following
S. pneumoniae and H. influenzae. According to reports
from 1992 to 2006, 15 − 20 % of acute otitis media epi-
sodes were caused by M. catarrhalis on the basis of cul-
tures of middle ear fluid obtained by tympanocentesis
[7, 16–18]. Colonization rate of M. catarrhalis in
Japanese children attending day-care centers was 34.6 %,
which followed S. pneumoniae (60.3 %) and H. influenzae
(53.2 %) in the pre-vaccine era [19]. Several reports from
countries where PCVs are widely used demonstrated that
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colonization by vaccine serotypes of pneumococcus were
decreasing, while colonization by the pneumococcus with
non-PCV serotypes H. influenzae and M. catarrhalis were
increasing, resulting in a change in the pathogens that
cause otitis media [7, 20, 21] and sinusitis [7, 22, 23].
However, with the recent inclusion of Hib vaccine and
PCV [13] in the national immunization program in Japan,
the colonization rate of M. catarrhalis may increase in the
near future.
M. catarrhalis is an important pathogen in respiratory
tract infections in children, but bacteremia is rare [24].
Several recent reports revealed that previously healthy im-
munocompetent patients developed Moraxella bacteremia
at a constant rate [24–27]. In the current study, however,
only one previously healthy child developed bacteremia
due to M. catarrhalis and the remaining seven patients
had underlying disease. A previous report described 11
cases of bacteremia due to M. catarrhalis and noted that
it should be considered in febrile children with underlying
immunodeficiency and upper respiratory tract infection
[8]. Ioannidis et al. noted that nearly 30 % of patients with
M. catarrhalis bacteremia had underlying respiratory fac-
tors including tracheostomy or dependence on mechanical
ventilation, and acute respiratory infections such as viral
pneumonia [28]. The authors also described an association
with chronic neurological debilities as one of the predis-
posing factors [28]. Similarly, we found that a quarter of
the patients had underlying respiratory diseases, and three
out of eight patients had chronic neurological problems.
More specifically, our study highlights the association of
medical devices, particularly trans-nasal devices, as inde-
pendent factors associated with bacteremia due to M. cat-
arrhalis compared with S. pneumoniae or H. influenzae.
Most isolates of M. catarrhalis produce beta-lactamases
in contrast to S. pneumoniae which acquire modest ampi-
cillin resistance through modification of the penicillin
binding proteins. Our findings suggests that modification
of empiric coverage to cover penicillinase producing M.
catarrhalis is a consideration for patients with underlying
disorders with trans-nasal devices who develop respiratory
tract infections.
The pathogenic association of medical devices and in-
vasive disease caused by M. catarrhalis is unclear. The
nasopharyngeal colonization of M. catarrhalis is quite
common among children, especially through infancy,
and M. catarrhalis forms biofilms and has been identi-
fied in the middle ears of children with otitis media [7].
Adherence of M. catarrhalis to the respiratory epithe-
lium and mucin molecules of the nasopharynx and the
middle ear is known to be a key step in the initiation of
infection [29, 30]. M. catarrhalis has also been found
intracellularly in subepithelial cell and lymphoid tissue
[31], with a possibility that the breach in the integrity of
the mucosal barrier by medical devices may also
contribute to the development of invasive infections. A
previous report identified the presence of endotracheal
tubes and frequent endotracheal tube suctioning as risk
factors for developing nosocomial infection due to M.
catarrhalis, which support our findings [32]. Moreover,
another report describes the association of respiratory
tract fragility with bacteremic pneumonia caused by M.
catarrhalis may reflect increased rates of oropharyngeal
colonization, enhancement of bacterial adherence to ab-
normal epithelium, and increased susceptibility of pul-
monary parenchyma to infection [28, 33]. According to
a study using an animal model, type IV pili of M. catar-
rhalis plays a crucial role in colonization of the nasopha-
ryngeal mucosa and biofilm formation [34]. In addition,
the biofilms produced by M. catarrhalis are similar to
the complicated structures produced by several bacteria,
such as Pseudomonas aeruginosa. Biofilm formation is
important in considering infections associated with for-
eign body, such as endotracheal tube [34, 35]. However,
it has yet to be revealed whether biofilms contribute to
pathogenesis of infections caused by M. cararrhalis. Fur-
ther basic and clinical studies are needed to clarify our
hypothesis.
A previous report that described the clinical and la-
boratory aspects of M. catarrhalis bacteremia in 17 chil-
dren showed that most patients with M. catarrhalis
bacteremia had modest elevation in body temperature
(mean ± SD: 37.3 ± 1.2 °C) and leukocytosis (mean ± SD:
12,070 ± 7569 /μL) [24]. In the current study, although
all patients had a maximum temperature >38.0 °C, the
fever tended to be mild and leukocyte count was 14,774
± 13,750/μL (mean ± SD), denoting similar tendency
with the previous report. Such data suggests that M. cat-
arrhalis is associated with relatively mild inflammation.
However, the patients’ immune statuses including neu-
trophil function, complement and humoral immunity,
which may influence the degree of inflammation, were
not fully investigated in the current study.
We acknowledge that there are several limitations to
this study. First, this study is a retrospective case–con-
trol-control study based on a single center experience in
Japan. In addition, there were few patients with M. cat-
arrhalis bacteremia. Thus, we performed only univariate
analyses, and therefore our results should be interpreted
carefully. Second, this study was conducted on patients
with bacteremia due to H. influenzae and S. pneumoniae
during a transition period of the national immunization
program in Japan before and after introduction of Hib
vaccine and PCV, which may influence patient back-
ground. Finally, the study evaluated the clinical charac-
teristics of the Moraxella bacteremia patients against
those with pneumococcal or Haemophilus bacteremia.
Therefore, our study is likely to underestimate the risk
factors that are common to the development of
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bacteremia caused by all three organisms. Hereafter,
collection and evaluation of national surveillance data re-
garding Moraxella bacteremia patients are required to
clarify epidemiological changes in the post-vaccine era
and the risk factors of patients with Moraxella
bacteremia.
Conclusions
Patients with bacteremia due to M. catarrhalis were
likely to have underlying diseases or conditions requiring
medical devices, particularly trans-nasal devices.
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